Pulmonx (NASDAQ:LUNG) Given New $5.00 Price Target at Canaccord Genuity Group

Pulmonx (NASDAQ:LUNG) had its price objective lowered by Canaccord Genuity Group from $6.00 to $5.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a report on Thursday. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.38.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $1.61 on Thursday. The company has a current ratio of 4.86, a quick ratio of 4.15 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $1.76 and a 200-day moving average price of $1.78. The company has a market cap of $66.41 million, a price-to-earnings ratio of -1.21 and a beta of 0.07. Pulmonx has a 12 month low of $1.31 and a 12 month high of $8.12.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. The company had revenue of $22.60 million for the quarter, compared to the consensus estimate of $21.73 million. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%. As a group, equities analysts anticipate that Pulmonx will post -1.55 EPS for the current year.

Insider Activity

In related news, CEO Glendon E. French III sold 67,813 shares of Pulmonx stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $96,972.59. Following the completion of the transaction, the chief executive officer directly owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This trade represents a 4.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 98,265 shares of company stock valued at $140,519. 6.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pulmonx

Institutional investors and hedge funds have recently made changes to their positions in the business. Corton Capital Inc. bought a new stake in shares of Pulmonx in the 2nd quarter worth approximately $32,000. Cerity Partners LLC purchased a new position in Pulmonx during the fourth quarter valued at $27,000. Opal Capital LLC bought a new stake in Pulmonx in the fourth quarter worth $29,000. Regatta Capital Group LLC bought a new stake in Pulmonx in the fourth quarter worth $30,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Pulmonx in the fourth quarter worth $31,000. Institutional investors own 91.04% of the company’s stock.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Company closed a five‑year credit facility for up to $60 million (initial $40M draw used to refinance existing debt, $20M undrawn tied to revenue milestones), extending debt maturities to 2031 and improving near‑term liquidity. Article Title
• Positive Sentiment: Q4 results beat estimates (EPS -$0.25 vs. consensus -$0.39; revenue $22.6M vs. ~$21.7M), with narrower net loss and improved adjusted EBITDA — evidence management points to of early operational improvement. Article Title
• Positive Sentiment: Broker support: D. Boral Capital reaffirmed a Buy and maintained a high $14 target, which can attract momentum buyers given the large upside vs. current levels. Article Title
• Neutral Sentiment: Margins and cost discipline showed progress (Q4 gross margin ~78%, operating expenses down ~11% Q/Q), supporting the path to profitability but dependent on revenue re‑acceleration. Article Title
• Neutral Sentiment: Canaccord trimmed its price target (from $6 to $5) but kept a Buy rating — indicates mixed analyst views (some support, some more cautious on near‑term upside). Article Title
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), signaling slower top‑line growth and capping near‑term upside despite cost cuts. Article Title
• Negative Sentiment: New credit facility is relatively expensive (SOFR +7.0% with a 3.75% floor and 2% PIK option) and includes warrants — provides liquidity but raises interest cost and potential dilution. Article Title
• Negative Sentiment: Multiple insider sales (including CEO, general counsel and others) were disclosed for March 2 — adds perceived selling pressure and can weigh on sentiment, even if sales were small dollar amounts. Article Title

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.